Please login to the form below

Not currently logged in

gastric cancer

This page shows the latest gastric cancer news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

CHMP meeting round-up. Among other highlights the CHMP backed two biosimilar medicines - Amgen’s Kanjinti version of Roche’s Herceptin (trastuzumab) for the treatment of breast and gastric cancer and ... It also gave its blessing to Clovis

Latest news

More from news
Approximately 4 fully matching, plus 70 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    There it is currently conducting a series of investigations in breast cancer to assess Xtandi's potential. ... It's not all been plain sailing for Astellas in oncology - a couple of candidates, notably rilotumumab, have fallen by the wayside in gastric

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214. ... 525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast / gastric cancer.

  • Pharma deals during October 2014 Pharma deals during October 2014

    Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in milestones for ADU 214 in the treatment of lung cancer. ... in breast and gastric cancer.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    100. Cancer Prevention Pharmaceuticals/ Zeria Tillotts Pharma. Exclusive licensing agreement for Europe and Japan. ... 100+. ACT Biotech/ Eddingpharm. Acquisition. Acquisition of 3 small molecule assets: Telatinib, a p3 ready VEGFr inhibitor for gastric

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...